Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
ReviewLysophospholipids and their receptors in the central nervous system☆
Highlights
► This is a review on CNS aspects of lysophospholipids (LPs) and their receptors. ► LPs are bioactive lipids originating from the cell membrane and include LPA and S1P. ► Cognate GPCRs account for LP biology, pathology and new therapeutics.
Introduction
Lysophospholipids (LPs) are phospholipid derivatives originating from cell membranes and two of the best-studied LPs are lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P). These two LPs were previously known as biosynthetic metabolites of cell membrane phospholipids, but they are now regarded as important regulators for diverse biological functions through activation of their specific cognate receptors. At present, there is a family of 11 bona fide G protein-coupled receptors (LPA1–6; S1P1–5) that link into multiple downstream effector pathways (Fig. 1). LPA and S1P receptors are present in various organ systems, which accounts for their diverse biological roles [1], [2], [3], [4]. Important LPA and S1P-mediated biological functions were discovered by studies utilizing genetic null mutants for LPA and S1P receptors [1], [4], [5]. Currently, there are 10 published receptor‐null mice for the following LPA or S1P receptors: LPA1, LPA2, LPA3, LPA4, LPA5, S1P1, S1P2, S1P3, S1P4, and S1P5, all of which have been used to uncover valuable receptor-mediated biological functions (summarized in Table 1).
The CNS is one of the biological systems markedly affected by LPA and S1P signaling. Many subtypes of LPA and S1P receptors are expressed in one or more CNS cell types, and their ligands are also enriched there [1], [6], [7]. Consequently, LPA and S1P signaling affects CNS cell types such as neuroblasts, neurons, astrocytes, and oligodendrocytes to influence cell survival, proliferation, migration, differentiation, and morphological changes (reviewed in [1], [3], [8], [9], [10], [11]). To date, LPA and/or S1P receptors have been identified as important factors in CNS development, as well as having roles in diseases, including MS [12], [13], fetal hypoxia and hydrocephalus [14], [15], [16], neuropathic pain [17], [18], [19], brain ischemic stroke [20], [21], neurotrauma [22], developmental disorders like schizophrenia, as well as hearing loss [23], [24], [25], seizures [26], [27], [28], and Sandhoff disease [29].
In this review, we will focus on the biological roles of LPA and S1P receptors in different CNS cell types, including neurons, astrocytes, and oligodendrocytes, and discuss their involvement in CNS diseases. Specifically, we discuss in vivo and in vitro data that were obtained from studies using LPA or S1P receptor null mutants. Involved cell types affected in the CNS include not only CNS lineages but also non-CNS lineages such as resident cell types like microglia, which will also be considered.
Section snippets
LPA and S1P receptor expression in the CNS
In the past decades, the biological activities of LPA and S1P were mechanistically unclear, with explanations ranging from detergent-like membrane perturbation, second messenger activities, to possible receptors. In 1996, the first LP receptor, LPA1, was identified in the ventricular zone of the embryonic brain [30], [31] with subsequent deorphanization based on sequence homology of both new LPA and S1P receptors [7], [32], [33], [34], [35], [36], [37], [38], [39], [40], [41]. Now, there is a
Biological functions of LPA and S1P receptors in CNS cell types
The discovery of the first LPA receptor, LPA1, and the role it plays in nervous system development, has served as a template for LP research in the CNS as well as other tissues. Since then, a variety of specific responses at cellular and tissue levels have been identified, including proliferation, morphological changes, cell migration, differentiation, and survival. This section will discuss biological functions of LPA and S1P receptors in CNS cell types, such as neuroblasts, neurons,
LPA and S1P receptors as promising therapeutic targets in CNS diseases
The biological functions of LPA and S1P signaling on CNS cell types have led to translational research to identify medically relevant roles for LP receptors. Genetic nulls, combined with pharmacological LP receptor modulators, have been utilized to validate therapeutic functions in CNS diseases. The clearest success of this research is FTY720, an S1P receptor modulator approved by the FDA in 2010 as a first oral MS therapy [12], [13]. This success has provided proof-of-concept for other
Conclusions
Since the discovery of the first LP receptor, LPA1, 11 receptors are now included in this family of 6 LPA and 5 S1P receptors. These bona fide GPCRs are widely and diversely expressed throughout the body and during development, to influence myriad biological as well as pathological processes. A growing number of studies using genetic null mutants for these LP receptor subtypes (LPA1, LPA2, LPA3, LPA4, LPA5, S1P1, S1P2, S1P3, S1P4, and S1P5) have clarified specific functions mediated by each,
Acknowledgements
We thank Danielle Letourneau for editorial assistance and Sook-Hyun Yoon for figure editing. We apologize for any oversights. This work was supported by the National Institutes of Health (NS048478 and DA019674) to JC, and the Korean National Research Foundation (2010‐0003058) and a Novartis Postdoctoral Fellowship (Novartis Pharma, AG) to JWC.
References (206)
- et al.
Biological roles of lysophospholipid receptors revealed by genetic null mice: an update
Biochim. Biophys. Acta
(2008) - et al.
Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis
Pharmacol. Ther.
(2008) - et al.
Lysophosphatidic acid (LPA) and its receptors
Curr. Opin. Pharmacol.
(2009) - et al.
LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease
Mol. Cell. Neurosci.
(2003) - et al.
Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain
J. Biol. Chem.
(2012) - et al.
The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia
Biochem. Biophys. Res. Commun.
(2009) - et al.
The S1P2 sphingosine 1-phosphate receptor is essential for auditory and vestibular function
Hear. Res.
(2006) - et al.
Deafness and stria vascularis defects in S1P2 receptor-null mice
J. Biol. Chem.
(2007) - et al.
Synaptic PRG-1 modulates excitatory transmission via lipid phosphate-mediated signaling
Cell
(2009) - et al.
Frequent spontaneous seizures followed by spatial working memory/anxiety deficits in mice lacking sphingosine 1-phosphate receptor 2
Epilepsy Behav.
(2011)
Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids
FEBS Lett.
Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid
J. Biol. Chem.
Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA
Genomics
LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation
J. Biol. Chem.
GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5
J. Biol. Chem.
Identification of p2y9/GPR23 as a novel G protein-coupled receptor for Lysophosphatidic acid, structurally distant from the Edg family
J. Biol. Chem.
Targeted deletion of LPA5 identifies novel roles for LPA signaling in the development of neuropathic pain
J. Biol. Chem.
The mouse lp(A3)/Edg7 lysophosphatidic acid receptor gene: genomic structure, chromosomal localization, and expression pattern
Gene
EDG receptors as a potential therapeutic target in retinal ischemia–reperfusion injury
Brain Res.
Lysophosphatidic acid influences the morphology and motility of young, postmitotic cortical neurons
Mol. Cell. Neurosci.
Expression and function of lysophosphatidic acid receptors in cultured rodent microglial cells
J. Biol. Chem.
Microglial activation state and lysophospholipid acid receptor expression
Int. J. Dev. Neurosci.
Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod
Am. J. Pathol.
Edg-8 receptors are preferentially expressed in oligodendrocyte lineage cells of the rat CNS
Neuroscience
Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes
Int. J. Dev. Neurosci.
Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1–3) in angiogenesis
FEBS Lett.
Lysophosphatidic acid stimulates neuronal differentiation of cortical neuroblasts through the LPA1-G(i/o) pathway
Neurochem. Int.
Exploratory, anxiety and spatial memory impairments are dissociated in mice lacking the LPA1 receptor
Neurobiol. Learn. Mem.
Deletion of lysophosphatidic acid receptor LPA1 reduces neurogenesis in the mouse dentate gyrus
Mol. Cell. Neurosci.
A new method of embryonic culture for assessing global changes in brain organization
J. Neurosci. Methods
Regulation of synaptic strength by sphingosine 1-phosphate in the hippocampus
Neuroscience
Sphingosine 1-phosphate modulates spinal nociceptive processing
J. Biol. Chem.
Evidence for biological effects of exogenous LPA on rat primary afferent and spinal cord neurons
Brain Res.
Endogenous sphingosine 1-phosphate regulates spontaneous glutamate release from mossy fiber terminals via S1P(3) receptors
Life Sci.
LPA receptors: subtypes and biological actions
Annu. Rev. Pharmacol. Toxicol.
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature
Pharmacol. Rev.
Lysophospholipid receptors: signaling and biology
Annu. Rev. Biochem.
Insights into the pharmacological relevance of lysophospholipid receptors
Br. J. Pharmacol.
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis
J. Pharmacol. Exp. Ther.
Lysophospholipid receptors
Annu. Rev. Pharmacol. Toxicol.
Effects of LPA and S1P on the nervous system and implications for their involvement in disease
Curr. Drug Targets
Roles for lysophospholipid S1P receptors in multiple sclerosis
Crit. Rev. Biochem. Mol. Biol.
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Nat. Rev. Drug Discov.
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya)
Discov. Med.
Stereotyped fetal brain disorganization is induced by hypoxia and requires lysophosphatidic acid receptor 1 (LPA1) signaling
Proc. Natl. Acad. Sci. U. S. A.
Lysophosphatidic acid signaling may initiate fetal hydrocephalus
Sci. Transl. Med.
Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling
Nat. Med.
Autotaxin and lysophosphatidic acid1 receptor-mediated demyelination of dorsal root fibers by sciatic nerve injury and intrathecal lysophosphatidylcholine
Mol. Pain
Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases
Neurol. Res.
Modulation of LPA receptor expression in the human brain following neurotrauma
Cell. Mol. Neurobiol.
Cited by (0)
- ☆
This article is part of a Special Issue entitled Advances in Lysophospholipid Research.